Dantrolene Sodium
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01219 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 47 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | malignant hyperthermia, susceptibility to | KG + DL |
| 2 | moderate multiminicore disease with hand involvement | KG + DL |
| 3 | King-Denborough syndrome | KG + DL |
| 4 | congenital multicore myopathy with external ophthalmoplegia | KG + DL |
| 5 | central core myopathy | KG + DL |
| 6 | hypokalemic periodic paralysis | KG + DL |
| 7 | thyrotoxic periodic paralysis, susceptibility to | KG + DL |
| 8 | thyrotoxic periodic paralysis | KG + DL |
| 9 | myopathy, centronuclear | KG + DL |
| 10 | periodic paralysis (disease) | KG + DL |
| 11 | myopathy, tubular aggregate | KG + DL |
| 12 | X-linked centronuclear myopathy | KG + DL |
| 13 | distal myopathy, Tateyama type | KG + DL |
| 14 | congenital myopathy with excess of thin filaments | KG + DL |
| 15 | trigeminal nerve neoplasm | KG + DL |
| 16 | familial hemiplegic migraine | KG + DL |
| 17 | hypertrophic cardiomyopathy due to intensive athletic training | KG + DL |
| 18 | cirrhotic cardiomyopathy | KG + DL |
| 19 | hypertrophic cardiomyopathy | KG + DL |
| 20 | absence epilepsy | KG + DL |
| 21 | febrile infection-related epilepsy syndrome | KG + DL |
| 22 | early onset absence epilepsy | KG + DL |
| 23 | Lennox-Gastaut syndrome | KG + DL |
| 24 | endomyocardial fibrosis | KG + DL |
| 25 | congenital myopathy | KG + DL |
| 26 | perioral myoclonia with absences | KG + DL |
| 27 | faciodigitogenital syndrome | KG + DL |
| 28 | cryptogenic late-onset epileptic spasms | KG + DL |
| 29 | photosensitive occipital lobe epilepsy | KG + DL |
| 30 | atypical childhood epilepsy with centrotemporal spikes | KG + DL |
| 31 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 32 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 33 | glycogen storage disease due to acid maltase deficiency, late-onset | KG + DL |
| 34 | complex neurodevelopmental disorder | KG + DL |
| 35 | attention deficit-hyperactivity disorder | KG + DL |
| 36 | pseudotumor cerebri | KG + DL |
| 37 | karyomegalic interstitial nephritis | KG + DL |
| 38 | Joubert syndrome with renal defect | KG + DL |
| 39 | thoracic malformation | KG + DL |
| 40 | epilepsy, childhood absence, susceptibility to | KG + DL |
| 41 | adult familial nephronophthisis-spastic quadriparesia syndrome | KG + DL |
| 42 | acute encephalopathy with biphasic seizures and late reduced diffusion | KG + DL |
| 43 | rigid spine syndrome | KG + DL |
| 44 | serotonin syndrome | KG + DL |
| 45 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 46 | cardiomyopathy | KG + DL |
| 47 | trigeminal neuralgia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.